Industry Trend Analysis - German Generics Market Will Continue To Test Stada - FEB 2018

BMI View: Stada Arzneimittel ' s Group sales for 9M17 have rebounded compared to a year earlier; being the first results announced since Stada was acquired, this will be welcome news for the firm ' s new owners. However, the expectations for the final quarter are for a decline in sales, but for FY17 as a whole to end on a positive note. Turning around the continuing decline in sales in the German generics market, Stada ' s most important, will remain a challenge.

Stada Arzneimittel has announced its 9M17 results, for the period ended September 30 2017. Overall the firm reported good development during the period, with developments in the Belgian generics segment and Russian branded products segment proving to be the primary contributors. In addition, good business development in the German branded products segment in Q317 also had a positive impact.

Group sales for 9M17 reached EUR1,698.0mn (USD1,890.3mn), up by 10.1% over the EUR1,541.7mn reported a year earlier. Operating profit jumped by 18.4%, from EUR137.0mn to EUR204.9mn (USD228.1mn); net income also rose, but by a smaller amount, increasing by 8.9%, from EUR100.3mn to EUR109.2mn (USD121.6mn).

Strong Uptick In Group Sales
Stada's Top-Line Financial Results (EURmn)
Source: Stada Arzneimittel, BMI

This article is part of our Western Europe coverage. To access this article subscribe now or sign up for free trial